🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis

RecruitingNAAges 1 Hour - 24 MonthsAllUniversitair Ziekenhuis Brussel
NCT07316465 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Previous research has shown that some patients with atopic eczema have specific self-reactive antibodies, known as IgE autoantibodies, that react to their own skin cells, referred to as "self-reactive antibodies" or "autoantibodies". It is not yet known when and how these self-reactive antibodies develop, so this is what we aim to investigate. This study aims to examine the presence of self-reactive antibodies at birth. In other words, the investigators want to study the earliest stage of developing antibodies that target the body's own skin cells. Additionally, factors that contribute to the development of these self-reactive antibodies will be explored as well as the correlation with the development of atopic eczema. The study will involve newborns who are at an increased risk of developing atopic eczema due to a family history of asthma, hay fever, or atopic eczema. There will also

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Newborns who are planned to be born at the maternity ward of UZ Brussel with the following criteria: * 400 newborns with high-risk for AD-development (at least 1 parent or sibling with physician diagnosed atopic dermatitis AND/OR asthma AND/OR allergic rhinitis) * 100 newborns with low-risk for AD-development (no parents or siblings with history of atopic dermatitis AND/OR asthma AND/OR allergic rhinitis) Exclusion Criteria: * Newborns not born at the maternity ward of UZ Brussel * Parents with a poor understanding of Dutch, French or English * Newborns who are admitted post-partum to the neonatal intensive care unit (gestational age \<34 weeks) or with medical complications * Newborns with severe genetic abnormalities/birth defects * Newborns whose parents will not be able to attend the study visits for a period of 2 years (location, working hours)
💊

What it tests

  • Development of atopic dermatitis with/without IgE autoantibodies
📍

Where

1 site
Universitair Ziekenhuis (UZ) Brussel, Vrije Universiteit Brussel (VUB)
Jette, Belgium
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy